Akkermansia vs BPC-157 Oral (Gut)
A side-by-side research comparison of Akkermansia and BPC-157 Oral (Gut) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Akkermansia | BPC-157 Oral (Gut) |
|---|---|---|
| Full name | Akkermansia muciniphila (Pasteurized) | BPC-157 Oral (Stable Arginine Salt) |
| Category | Gut Health | Gut Health |
| Status | Novel food / Supplement | Research compound |
| Mechanism | Amuc_1100 outer membrane protein activates TLR2 signaling, strengthening gut barrier and improving metabolic endotoxemia. Stimulates mucin production by goblet cells. Enhances GLP-1 secretion and improves insulin signaling. | Upregulates VEGF and EGF receptors in GI mucosa, promotes angiogenesis at ulcer/lesion sites, modulates nitric oxide system, and interacts with dopamine and serotonin systems in the gut-brain axis. |
| Molecular weight | Whole organism (not applicable) | 1419 Da |
| Half-life | Colonizes mucus layer; effects persist with continued use | ~4 hours (local GI transit) |
| Bioavailability | Oral - pasteurized form survives transit; live form colonizes | Limited systemic absorption; primary action is local GI |
| Typical dose | 10 billion CFU (pasteurized) or 100mg membrane extract | 250-500 mcg |
| Frequency | Daily | 2x daily on empty stomach |
| Route | Oral capsule | Oral capsule or sublingual |
Akkermansia reported benefits
- Improved metabolic markers
- Reduced insulin resistance
- Gut barrier strengthening
- Weight management support
- Reduced systemic inflammation
- Enhanced GLP-1 secretion
BPC-157 Oral (Gut) reported benefits
- Gastric ulcer healing
- Esophageal repair (GERD)
- Intestinal inflammation reduction
- IBD symptom relief
- Gut-brain axis support
- NSAID damage protection
Related comparisons
Research and educational reference only. Not medical advice.